Information is not forthcoming with with this company. March 25 ' we have partnered with a company which we will announce very soon that has formulated it ( zafirlukust) into a dry powder inhaler'. Very soon was 4 months later. Christian Behrenbruch would appear to be a lone ranger in trying to hold Aussie biotech companies accountable. He quite correctly points out the lack of information provided to shareholders on our lupus trial... Where is the 4th cohort? Why only report 2 time points? What about all the other biomarkers? Very frustrating.
IVX Price at posting:
1.4¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)